Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer - Data from CaPSURE
Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer - Data from CaPSURE
复制标题
DOI：
10.1097/01.ju.0000091426.55735.f0
复制
发表时间：
2003-11-01
影响因子：
6.6
通讯作者：
Lubeck, DP
中科院分区：
文献类型：
--
作者：
Downs, TM;Sadetsky, N;Lubeck, DP
目的：与前列腺癌根治术(RP)患者比较，比较近距离放射治疗(BMT)对一般和特定疾病的健康相关生活质量(HRQOL)的影响。材料和方法：我们研究了419名新诊断的前列腺癌患者，这些患者登记在CaPSURE(前列腺癌战略泌尿学研究奋进组织)数据库中，其主要治疗是后装治疗(92例)或前列腺癌根治术(327例)。采用兰德36项健康状况调查表和UCLA前列腺癌指数在治疗前和治疗后2年内每隔6个月测量一次HRQOL。结果：接受BMT和RP治疗的患者在治疗后的一般HRQOL方面差异无统计学意义。治疗后18至24个月，两组患者在大多数一般领域都表现出早期的功能损害，大部分领域的评分恢复或接近基线。BMT组治疗后0~6个月尿功能评分(84.5，SD 18.7)显著高于RP组(63.3，SD 26.6)。BMT组和RP组治疗后0~6个月的排尿障碍评分分别为67.7分、67.4分和29.1分，差异无统计学意义(P>0.05)。两组患者的性功能均有下降，但均未恢复到治疗前水平。结论：总体上，BMT和RP是耐受性良好的手术，可引起一般HRQOL的轻微变化。在接受骨髓移植或RP治疗的患者中，特定疾病的HRQOL模式不同。治疗后的基线和系列HRQOL测量可以提供有关局限性前列腺癌治疗后预期生活质量的有价值的信息。
Purpose: We measured the impact brachytherapy monotherapy (BMT) has on general and disease specific health related quality of life (HRQOL) compared to patients treated with radical prostatectomy (RP).Materials and Methods: We studied 419 men with newly diagnosed prostate cancer who enrolled in CaPSURE (Cancer of the Prostate Strategic Urological Research Endeavor) data base whose primary treatment was brachytherapy monotherapy (92) or radical prostatectomy (327). The validated RAND 36-Item Health Survey and the UCLA Prostate Cancer Index were used to measure HRQOL before treatment and at 6-month intervals during the first 2 years after treatment.Results: Patients treated with BMT or RP did not differ greatly in general HRQOL after treatment. Both treatment groups showed early functional impairment in most general domains with scores returning to or approaching baseline in most domains 18 to 24 months after treatment. Patients treated with BMT had significantly higher urinary function scores at 0 to 6 months after treatment (84.5, SD 18.7) than patients treated with RP (63.3, SD 26.6). Urinary bother scores at 0 to 6 months after treatment were not significantly different between patients treated with BMT (67.7, SD 31.2) and those treated with RP (67.4, SD 29.1). Both treatment groups had decreases in sexual function that did not return to pretreatment levels.Conclusions: Overall BMT and RP are well tolerated procedures that cause mild changes in general HRQOL. Disease specific HRQOL patterns are different in patients treated with BMT or RP. Baseline and serial HRQOL measurements after treatment can provide valuable information regarding expected quality of life outcome after treatment for localized prostate cancer.